Factoid: Of the total debt+equity capital raised by US biotech companies in 2010, only 0.4% was raised by the lowest quintile of companies. Source: Ernst & Young (http://finance.yahoo.com/news/Despite-Renewed-Growth-in-prnews-696894244.html?x=0&.v=1 )